Quinidine 奎尼丁

CAS 56-54-2 MFCD00135581

化学结构图

56-54-2
SMILES:

化学属性

Mol. FormulaC20H24N2O2
Mol. Weight324.42
Density0.05
Melting Point168-172°C
TSCAYes
Solubility0.05 G/100 ML (20 ºC)
Stability对光敏感
Boiling Point495.9°C at 760 mmHg

别名和识别编码

Chemical NameQuinidine
CAS Number56-54-2
Alfabeta NameMETHOXYQUINOLINYLVINYLQUINUCLIDINYLMETHANOL SRSR16424552(((())))--------,,
MDL NumberMFCD00135581
Synonym Quinidine (15% dihydroquinidine) {LY} Quinidine (15% dihydroquinidine) {} {LY} Quinidine (15% dihydroquinidine) {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} {} { {} {} {} {} {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {} {} {} {} {} {LY} Quinidine (15% dihydroquinidine) {} {} {} {} {} {} {} {} {}
EC Number200-279-0
Beilstein Registry Number23(2)414
PubChem Substance ID87575544
Merck Number8060
Reaxys-RN3654871
Chemical Name Translation奎尼丁
Wiswesser Line NotationT66 BNJ HO1 EYQ- DT66 A B CNTJ A1U1
LabNetwork Molecule IDLN00173655
Canonical SMILESC=C[C@H]1C[N@](CC[C@H]1C2)[C@@]2([H])[C@@H](O)C3=CC=NC4=CC=C(OC)C=C34
信息真实价格透明    资金保障    专业采购外包团队在线服务   
信息真实价格透明    资金保障    专业采购外包团队在线服务   
品牌质保精细包装    现货库存    一流品牌服务   

分类

  • {SA} Approved Therapeutics/Drug Candidates, Asymmetric Synthesis, Bayer, Bioactive Small Molecules, Cell Biology, Cell Signaling and Neuroscience, Chemical Synthesis, Chiral Catalysts, Ligands, and Reagents, Cinchona Alkaloids, Ion Channels, Monovalent Ion Channels, Other Sodium Channel Modulators, Privileged Ligands and Complexes, Q, Sodium Channel Modulators, Voltage-gated Ion Channels, Wyeth
  • {SNA} Appro
  • {SNA} Approved Therapeutics/Drug Candidates, Asymmetric Synthesis, Bayer, Bioactive Small Molecules, Cell Signaling and Neuroscience, Chemical Synthesis, Chiral Catalysts, Ligands, and Reagents,

产品应用

  • Class IA 抗心律失常药; 钾通道阻断剂;也用作手性催化剂。

相关文献及参考

  • Merck:14,8060
  • Merck:14,8060 Beilstein:23(2)414

安全信息

Warnings IRRITANT
Signal word
GHS Symbol
WGK Germany3
Safety Statements
Risk Statements
  • R22 Harmful if swallowed 吞咽有害
Precautionary statements
  • P301+P310+P330
  • P264 Wash hands thoroughly after handling. 处理后要彻底洗净双手。
  • P501 Dispose of contents/container to..… 处理内容物/容器.....
  • P261 Avoid breathing dust/fume/gas/mist/vapours/spray. 避免吸入粉尘/烟/气体/烟雾/蒸汽/喷雾。
  • P305+P351+P338
  • P332+P313
  • P405 Store locked up. 上锁保管。
  • P301+P310
  • P270 Do not eat, drink or smoke when using this product. 使用本产品时不要吃东西,喝水或吸烟。
Hazard statements
  • H301 Toxic if swallowed 吞食有毒
Personal Protective Equipment dust mask type N95 (US), Eyeshields, Faceshields, Gloves
RTECSVA4725000
Storage condition 2-8°C, protect from light, stored under nitrogen {LY} 2-8°C, protect from light, stored under nitrogen Light Sensitive {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C, protect from light, stored under nitrogen {} {} {} {} {} {} {} {} {} {} {} {} {LY} 2-8°C, protect from l
Hazard Codes Xn
UN Number UN 2811 6.1/PG 3 2811
Packing GroupIII
Hazard Class6.1
TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intramuscular
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 200 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   27ZIAQ "Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes,
   C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973
   Volume(issue)/page/year: -,232,1973

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intravenous
SPECIES OBSERVED        : Rodent - rat
DOSE/DURATION           : 23 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   JPETAB Journal of Pharmacology and Experimental Therapeutics.  (Williams &
   Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)  V.1-    1909/10-
   Volume(issue)/page/year: 128,22,1960

TYPE OF TEST            : LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE       : Subcutaneous
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 400 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   AEPPAE Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und
   Pharmakologie.  (Berlin, Ger.) V.110-253, 1925-66.  For publisher
   information, see NSAPCC.  Volu

TYPE OF TEST

TYPE OF TEST            : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE       : Intraperitoneal
SPECIES OBSERVED        : Rodent - mouse
DOSE/DURATION           : 135 mg/kg
TOXIC EFFECTS :
   Details of toxic effects not reported other than lethal dose value
REFERENCE :
   AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans
   Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium)  V.4-   
   1898-  Volume(issue)/page/year: 137,410,1962

{hazard_

其他信息

  • Alfa Aesar:(+)-奎尼丁 (+)-Quinidine(56-54-2)
  • 毒性反应:奎尼丁可以产生两种毒性反应,一种与剂量大小有关,当每日口服3g以上奎尼丁时,往往产生QRS波群增宽,有时可超过原来的50%以上。房室传导阻滞及明显的窦性心动过缓,是停药的指征。另一种毒性反应与剂量大小无关,例如每日服用0.2~2.0g奎尼丁时,约有2%~4%的病人发生室性早搏、室性心动过速甚至心室颤动而死亡。室速及室颤多表现为扭转型室性心动过速,目前认为系由于延长了心室肌的复极时间(常有Q-T间期明显延长),心肌各部分复极时间不均性(dispersion)增加,易损期增宽加上心肌普遍传导障碍,易引起连续且紊乱的折返激动,特别是心肌条件原已不好的患者,或具有电解质紊乱的患者,使用奎尼丁时更应慎重,当Q-Tc>0.50s时,更应谨慎给药。现已证实,奎尼丁的副作用是剂量依赖性的,因此,临床应用的剂量不宜过大。应用奎尼丁复律的患者为防止意外均应住院,医务人员应密切观察病人心率、血压、血钾和监测心电图。有下列情况之一者应立即停药:(1)心率明显减慢,少于60次/min;(2)收缩压下降,低于12.0KPa (90mmHg);(3) Q-Tc间期延长≥30%;(4) QRS波群时间延长达25%以上;(5)T波幅度降低,出现双峰;(6)频发性室性早搏可除外其他原因;(7)尖端扭转型室速。
  • 抗心律失常药:奎尼丁为抗心律失常药。常用其硫酸盐但也有用盐酸盐和葡萄糖酸盐的。硫酸奎尼丁为白色结晶性粉末,无臭,味极苦,熔点175~176℃,易溶于水,微溶于乙醇。 奎尼丁是从茜草科植物金鸡钠(Cinchona ledgeriana,Moens)树皮中提取的一种生物碱,对细胞膜有直接作用,主要抑制钠离子的跨膜运动,对心脏的自律性、传导性、应激性和收缩性均有直接抑制作用,兼有对心脏抗胆碱能作用。适用于心房颤动、心房扑动、室上性和室性心动过速的复律和预防,恶性过早搏动的治疗和预防。 奎尼丁是奎宁的右旋体,二者具有相似的药理性质,但奎尼丁对心脏的作用比奎宁强5~10倍,它与心肌细胞膜上钠通道的脂蛋白结合,使通道闸门变窄,阻止Na+内流,导致0相去极化速度降低,传导减慢。因第4相去极化速度减慢而降低心肌自律性,抑制异位节律点。减慢3相K+外流,从而延长不应期。此外还抑制心肌收缩力和具有抗副交感和交感神经作用。奎尼丁阻断α 受体,使血管扩张,尤其静注时可引起血压急剧下降,故不能静注给药。 以上信息由ChemicalBook的Andy编辑整理。
  • 不良反应:本品治疗指数低,约1/3的患者发生不良反应。 ①心血管:产生心脏停搏及传导阻滞,较多见于原有器质性心脏病患者,也可发生室性早搏、室性心动过速及室颤。本品可使血管扩张产生低血压,个别可发生脉管炎。 ②胃肠道不良反应很常见,包括恶心、呕吐、痛性痉挛及腹泻,可能为直接刺激作用所致。 ③金鸡纳反应:可产生耳鸣、胃肠道障碍、心悸、惊厥、头疼及面红。视力障碍如视物模糊、畏光、复视、色觉障碍、瞳孔散大、暗点及夜盲。听力障碍、发热、荨麻疹、局部水肿、眩晕、震颤、头晕目眩、兴奋、昏迷、忧虑,甚至死亡。一般与剂量有关。 ④特异质反应:头晕、恶心、呕吐、冷汗、休克、青紫、呼吸抑制或停止。与剂量无关。 ⑤过敏反应:各种皮疹,尤以荨麻疹、瘙痒多见,发热、哮喘、血小板减少、粒细胞缺乏、贫血(再生不良性或溶血性)、肝炎、虚脱、猝死。与剂量无关。 ⑥肌肉:使重症肌无力加重。
  • 药物相互作用:1. 奎尼丁与其他抗心律失常药合用时有相加作用。 2. 与抗凝血药合用时可使两药互相影响,应注意调整两药剂量。 3. 苯巴比妥及苯妥英钠可使本品肝内代谢加速,使奎尼丁的血药浓度降低。 4. 与地高辛合用,可增加地高辛的血药浓度。 5. 与抗胆碱药合用,可增加抗胆碱药效能; 与拟胆碱药合用,可减弱拟胆碱能药效能; 与神经肌肉阻滞药尤其是筒箭毒碱、琥珀胆碱合用,可使其呼吸抑制作用增强。 6. 与钾制剂合用可使本品增效,而低血钾则使本品减效。 7. 与β受体阻滞剂合用可加重对窦房结和房室结的抑制作用。 8. 与降压药合用可增强降压和扩血管作用。 9. 与利福平合用,可使本品血药浓度降低。 10. 尿液碱化剂如乙酰唑胺、抗酸药或碳酸氢盐等,可增加肾小管对奎尼丁的重吸收而致本品血浓度增高,从而引起中毒反应。
  • 检测方法:HPLC,Rotation
  • F:8
  • {C

系列性分类


相关产品推荐